Welcome to our dedicated page for Nanovibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on Nanovibronix stock.
This page provides a historical news feed for NanoVibronix, Inc. under the ticker NAOV, which later changed its corporate name to ENvue Medical, Inc. and its Nasdaq ticker to FEED. The archived coverage reflects the company’s evolution as a medical technology business focused on non-invasive therapeutic systems and minimally invasive navigation platforms for enteral care and related clinical applications.
News items associated with NAOV include announcements about the company’s acoustic-based therapeutic technologies, such as PainShield and UroShield, which use proprietary low-intensity surface acoustic wave technology and are intended to treat pain, reduce bacterial colonization, and disrupt biofilms in home or care settings. Releases also describe developments around the UroShield Kit, including its addition to the UK National Health Service Drug Tariff Part IX and the resulting prescription reimbursement pathway across the UK.
Another major theme in the NAOV news history is the integration and expansion of the ENvue Navigation Platform, a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. Company communications highlight FDA 510(k) clearance for adult use, real-time bedside visualization of tube movement, and plans to build a broader enteral-feeding ecosystem around this platform. Additional stories cover training initiatives, such as the Oscar training aid for naso-enteral feeding procedures, and intellectual property developments related to navigation technology.
Investors and observers can use this NAOV news archive to trace key milestones such as the strategic shift toward enteral navigation, financing transactions disclosed in press releases, and the formal rebranding to ENvue Medical, Inc. For the most recent developments after the name and ticker change, subsequent news is released under the FEED symbol.
NanoVibronix, Inc. (NASDAQ: NAOV) announced successful independent life expectancy testing for its PainShield device, affirming that it met all functionalities required. The testing, conducted by Carmel Labs in Israel, confirms the device’s reliability. CEO Brian Murphy indicated that the results will support their pending application for Medicare coverage, following a prior denial in September 2022 due to insufficient data. This advancement is expected to enhance the product's market availability and potential reimbursement opportunities.
NanoVibronix, Inc. (NASDAQ: NAOV) has filed a provisional patent application for its enhanced UroShield device, titled "Multiple Frequency Surface Acoustic Waves for Internal Medical Device." The newly developed UroShield Ultra aims to improve catheter coupling and reduce bacterial infections with multiple actuators operating at various frequencies. CEO Brian Murphy emphasized its role in preventing Catheter Associated Urinary Tract Infections (CAUTI), a leading source of hospital-acquired infections. This innovation strengthens NanoVibronix's intellectual property portfolio and its position in the medical device market.
NanoVibronix, Inc. (NASDAQ: NAOV) announced positive evaluation results for its UroShield device at a recent medical conference. The report, conducted by clinicians from the Royal National Orthopaedic Hospital, indicates a decrease in blockages and infections, as well as increased patient satisfaction with catheters. The device is believed to improve quality of life and reduce healthcare costs for patients with spinal cord injuries. CEO Brian Murphy emphasized the significant market opportunity, as approximately 285,000 individuals in the U.S. and 50,000 in the UK live with such injuries.
NanoVibronix, Inc. (NASDAQ: NAOV) announced compliance with Nasdaq requirements on February 28, 2023, closing a prior listing matter regarding the $1.00 bid price. The company was granted an extension by the Nasdaq Hearings Panel on October 17, 2022, to regain compliance by February 23, 2023. NanoVibronix specializes in portable medical devices like UroShield® and PainShield® that utilize patented surface acoustic wave technology. These devices are designed for at-home use and aim to provide therapeutic benefits for various medical applications.
NanoVibronix, Inc. (NASDAQ: NAOV) has announced the launch of a month-to-month rental program for its medical devices, PainShield and UroShield, effective March 1, 2023. This initiative aims to improve patient accessibility and convenience, allowing individuals with valid prescriptions to rent these devices at affordable rates. The CEO, Brian Murphy, expressed confidence that the program will qualify for Medicare reimbursement, with additional supplies available for purchase separately. The company has applied for Medicare reimbursement, expecting a decision by May 2023 and implementation by October 1, 2023.
NanoVibronix, Inc. (NASDAQ: NAOV) announced a 1-for-20 reverse stock split effective on February 8, 2023, at 4:05 PM. The common stock will start trading on a split-adjusted basis on February 9, 2023. The reverse split reduces outstanding shares from approximately 32.9 million to about 1.6 million, while the share par value remains unchanged. This decision follows stockholder approval received on December 15, 2022, granting the board discretion to execute a reverse split within specified ratios. Stockholders’ percentage interests will remain unaffected.
NanoVibronix, Inc. (NASDAQ: NAOV) announced positive interim results from lifecycle testing of its PainShield product. This follows a setback where the Centers for Medicare & Medicaid Services (CMS) denied reimbursement due to insufficient life expectancy testing. The company has commissioned Carmel Labs to conduct this testing and will submit the positive results to CMS.
Additionally, the potential enactment of the bipartisan NOPAIN Act could significantly increase demand for PainShield by allowing separate Medicare reimbursement for non-opioid pain management alternatives. This legislative effort aims to expand access to devices like PainShield, which are designed for home use.
NanoVibronix, Inc. (NASDAQ: NAOV) held its 2022 annual stockholder meeting virtually, where several resolutions were passed. The Board of Directors now consists of eight members for a one-year term. A significant resolution passed allowing a reverse stock split of shares at a ratio between 1-for-2 and 1-for-50. Additionally, the 2014 Long-Term Incentive Plan was amended to increase the number of shares reserved by 1,518,000 shares. However, proposals to classify the Board and increase authorized shares were rejected.
NanoVibronix, Inc. (NASDAQ: NAOV) has partnered with Peak Medical, Ltd. to enhance distribution capabilities for its continence care products in the UK. This collaboration follows NHS Supply Chain Approval, allowing Peak Medical to sell the UroShield device, aimed at reducing risks associated with Catheter Associated Urinary Tract Infections (CAUTIs). With strong demand from the National Health Service, the partnership is expected to boost product uptake and improve patient care.
NanoVibronix, Inc. (NASDAQ: NAOV) has successfully completed a registered direct offering, selling 4,800,000 shares at $0.50 each, generating gross proceeds of $2.4 million. The funds will be utilized for general working capital purposes. The offering was facilitated by H.C. Wainwright & Co. under a shelf registration statement. This transaction allows the company to enhance its financial flexibility and continue developing its proprietary surface acoustic wave technology for medical applications. The offer was conducted under SEC regulations.